CCS and breast carcinoma: In studies of MDA‐MB‐231 cells (TNBC) and MCF‐7 cells (ER + BC), exogenous inhibitors DC_AC50 of CCS and endogenous silencing of CCS both inhibit the growth and migration of breast cancer cells by inhibiting the ROS‐mediated MAPK/ERK pathway activity [30].